Navigation Links
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Date:3/2/2009

Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia

SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the most common and debilitating manifestation of opioid-bowel dysfunction (OBD). The Phase 2 study of NKTR-118 is terminating early on the basis of overwhelming evidence of efficacy at two different dose levels of 25 mg once daily and 50 mg once daily. The study achieved a clinically meaningful and highly statistically significant, dose-dependent increase in spontaneous bowel movements (SBMs) from baseline after the first week of NKTR-118 treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). Patients receiving the 25 mg dose of NKTR-118 had an average of 5.1 SBMs during the first week of treatment as compared to 1.5 SBMs per week during the baseline period. Patients receiving the 50 mg dose of NKTR-118 had an average of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment period (p <0.01). More importantly, in the 25 mg and 50 mg dose cohorts, there was no reversal of analgesia as measured by a change in pain Numerical Rating Scale (NRS) and no increase in opiate use.

"These data show that NKTR-118 taken orally once-daily at the 25 mg and 50 mg dose levels dramatically increased bowel movements within the first week of treatment for patients with OIC," said Lynn R. Webster, M.D., Medical Director, Lifetre
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
8. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
9. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
10. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... - The Canadian Epilepsy Alliance (CEA) is thrilled to announce ... children about the most common neurological disorder in ... comic series tells a fictional story based on the experiences ... with epilepsy. "Despite the fact that epilepsy ... misinformation and lack of awareness out there," says Gail ...
(Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
(Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Hewlett-Packard (NYSE: HPQ - Free Report ), ... Inc. (NYSE: SB - Free Report ), GlaxoSmithKline plc ... N.V. (NYSE: FI - Free Report ). ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
(Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
Breaking Medicine News(10 mins):Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
... July 9, 2009 The President of the ... statement today on President Obama,s nomination of Francis Collins, M.D., ... Health (NIH):,"At no other time in recent memory has there ... in the power of science to deliver solutions to the ...
... Bioheart, Inc. (OTC Bulletin Board: BHRT) (the "Company") ... July 7, 2009, Bioheart, Inc. (the "Company") has received proceeds ... common stock and warrants under its current offering under Regulation ... Common Stock to be issued in connection with the Offering ...
... Parsippany took top honors in the state,s first-ever 100-day ... on June 2nd. With participating residents losing an average of ... pounds, Parsippany was presented with a plaque and Morris County ... , Residents throughout northern and central New Jersey also participated ...
... , ... and Directory Helps Attendees and Exhibitors,Connect at AAMSE Conference and Beyond. , ... Arlington, VA (PRWEB) July 9, 2009 -- MarketArt ... enhanced attendee experience at the American Association of Medical Society Executives (AAMSE) 2009 ...
... Institute of Technology (Caltech) and the Scripps Research Institute have ... chemicals that have the potential to take the place of ... James R. Heath, the Elizabeth W. Gilloon Professor and ... M. Keck Professor of Chemistry at the Scripps Research Institute ...
... United States Senate Committee on Small Business ... Member Olympia J. Snowe, R-Maine, today convened a ... relate to small businesses. Participants at the roundtable, ... the Perspective of Small Businesses," included U.S. Sen. ...
Cached Medicine News:Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 2Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 3Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 2Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 3Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
Medicine Products: